Raphael Pharmaceutical (RAPH) Free Cash Flow Growth (1y) (2021 - 2025)
Raphael Pharmaceutical (RAPH) Free Cash Flow Growth (1y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 134.35% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 17.21% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -37.45% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 58.76% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 97.24% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 43.69% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 35.56% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 174.19% |
| Sep 30, 2025 | 78.75% |
| Jun 30, 2025 | 86.24% |
| Mar 31, 2025 | -20.81% |
| Dec 31, 2024 | 29.55% |
| Sep 30, 2024 | 84.03% |
| Jun 30, 2024 | -1.40% |
| Mar 31, 2024 | 56.64% |
| Dec 31, 2023 | 68.23% |
| Sep 30, 2023 | -229.61% |
| Jun 30, 2023 | 13.31% |
| Mar 31, 2023 | -386.59% |
| Dec 31, 2022 | 60.65% |
| Sep 30, 2022 | 45.91% |
| Jun 30, 2022 | 18.69% |
| Mar 31, 2022 | 36.43% |
| Dec 31, 2021 | -50.43% |